Aliases & Classifications for Sensory Peripheral Neuropathy

MalaCards integrated aliases for Sensory Peripheral Neuropathy:

Name: Sensory Peripheral Neuropathy 12 15
Sensory Neuropathy 12 76 29 55 6 73
Hereditary Sensory and Autonomic Neuropathies 44 73
Neuropathy, Sensory and Autonomic, Hereditary 40
Peripheral Sensory Neuropathy 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2491
ICD9CM 35 356.2
MeSH 44 D009477
NCIt 50 C3501

Summaries for Sensory Peripheral Neuropathy

Disease Ontology : 12 A neuropathy that involves damage to nerves of the peripheral nervous system.

MalaCards based summary : Sensory Peripheral Neuropathy, also known as sensory neuropathy, is related to charcot-marie-tooth disease, x-linked dominant, 1 and charcot-marie-tooth disease, axonal, type 2b, and has symptoms including hyperesthesia, sciatica and neurologic symptoms. An important gene associated with Sensory Peripheral Neuropathy is GDAP1 (Ganglioside Induced Differentiation Associated Protein 1), and among its related pathways/superpathways are Guidance Cues and Growth Cone Motility and Neural Crest Differentiation. The drugs Gabapentin and gamma-Aminobutyric acid have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Peripheral neuropathy (PN) is damage to or disease affecting nerves, which may impair sensation,... more...

Related Diseases for Sensory Peripheral Neuropathy

Diseases related to Sensory Peripheral Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Related Disease Score Top Affiliating Genes
1 charcot-marie-tooth disease, x-linked dominant, 1 32.2 GDAP1 GJB1 MPZ
2 charcot-marie-tooth disease, axonal, type 2b 32.1 GJB1 MPZ PMP22 SPTLC1
3 peripheral nervous system disease 28.3 GDAP1 GJB1 MAG MFN2 MPZ MTMR2
4 neuropathy 27.4 GDAP1 GJB1 MFN2 MPZ NGF PMP22
5 hereditary sensory and autonomic neuropathy type 1 12.7
6 neuropathy, hereditary sensory and autonomic, type iia 12.4
7 insensitivity to pain, congenital, with anhidrosis 12.4
8 hereditary sensory neuropathy 12.4
9 hereditary motor and sensory neuropathy v 12.3
10 neuropathy, hereditary sensory and autonomic, type vii 12.3
11 neuropathy, hereditary sensory and autonomic, type iii 12.3
12 neuropathy, hereditary sensory and autonomic, type v 12.3
13 neuropathy, hereditary sensory and autonomic, type viii 12.3
14 deafness, x-linked 5 11.4
15 spinocerebellar ataxia, autosomal recessive 16 11.1
16 x-linked hereditary sensory and autonomic neuropathy with deafness 11.1
17 posterior column ataxia with retinitis pigmentosa 11.0
18 cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia 11.0
19 congenital hypomyelination neuropathy 10.7 MPZ PMP22
20 foot drop 10.7 MPZ PMP22
21 roussy-levy hereditary areflexic dystasia 10.6 MPZ PMP22
22 sensory neuropathy type 1 10.6 GJB1 SPTLC1
23 charcot-marie-tooth disease, axonal, type 2f 10.6 GJB1 MPZ
24 charcot-marie-tooth disease, type 4b3 10.5 GDAP1 MTMR2
25 brachial plexus neuropathy 10.5 GJB1 PMP22
26 charcot-marie-tooth neuropathy type 1 10.5 GJB1 MPZ PMP22
27 charcot-marie-tooth disease, demyelinating, type 1f 10.5 GJB1 MPZ PMP22
28 niemann-pick disease, type a 10.4 MAG MPZ
29 chronic inflammatory demyelinating polyradiculoneuropathy 10.4 MPZ PMP22
30 polyradiculoneuropathy 10.3 MAG MPZ PMP22
31 axonal neuropathy 10.3 GDAP1 MFN2 PMP22
32 pelizaeus-merzbacher disease 10.3 MAG MPZ PMP22
33 neuritis 10.3 MAG MPZ PMP22
34 amyotrophic neuralgia 10.2 GJB1 PMP22 PRX
35 charcot-marie-tooth disease, demyelinating, type 4f 10.2 GDAP1 MTMR2 PRX
36 charcot-marie-tooth disease, type 4b2 10.2 GDAP1 MTMR2 PRX
37 charcot-marie-tooth disease, type 4b1 10.2 GDAP1 MTMR2 PRX
38 charcot-marie-tooth disease, type 4a 10.2 GDAP1 MTMR2 PRX
39 charcot-marie-tooth disease, demyelinating, type 1b 10.2 GJB1 MPZ MTMR2 PMP22
40 polyneuropathy 10.1 GDAP1 MAG MPZ PMP22
41 hereditary neuropathy with liability to pressure palsy 10.1 LITAF MPZ PMP22
42 charcot-marie-tooth disease, demyelinating, type 1c 10.1 LITAF MPZ PMP22
43 demyelinating polyneuropathy 10.0 MAG NGF PMP22
44 diabetic autonomic neuropathy 9.9 NGF NTF3
45 plexopathy 9.9 NGF PMP22
46 tabes dorsalis 9.8 FXN SPTLC1
47 aging 9.7
48 vitamin b12 deficiency 9.7
49 demyelinating disease 9.7
50 diabetic neuropathy 9.7 MPZ NGF NTF3 PMP22

Graphical network of the top 20 diseases related to Sensory Peripheral Neuropathy:



Diseases related to Sensory Peripheral Neuropathy

Symptoms & Phenotypes for Sensory Peripheral Neuropathy

UMLS symptoms related to Sensory Peripheral Neuropathy:


hyperesthesia, sciatica, neurologic symptoms, dysesthesia

GenomeRNAi Phenotypes related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

26 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.85 FGD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.85 FGD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.85 SLC12A6
4 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.85 NTF3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.85 SLC12A6 FGD4 GJB1 NTF3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.85 NTF3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.85 FGD4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.85 FGD4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.85 GJB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.85 FGD4
11 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.85 NTF3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.85 GJB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.85 GJB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.85 SLC12A6
15 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.85 NTF3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.85 FGD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.85 GJB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.85 SLC12A6
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.85 GJB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.85 SLC12A6
21 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.85 SLC12A6
22 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.85 SLC12A6
23 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.85 GJB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.85 GJB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.85 FGD4
26 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.85 NTF3
27 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.85 SLC12A6
28 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.85 SLC12A6
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.85 NTF3
30 Increased shRNA abundance (Z-score > 2) GR00366-A-92 9.85 FGD4
31 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.85 SLC12A6

MGI Mouse Phenotypes related to Sensory Peripheral Neuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 FGD4 FXN GDAP1 GJB1 MAG MFN2
2 homeostasis/metabolism MP:0005376 10.07 SPTLC1 FLVCR1 FXN GDAP1 GJB1 LITAF
3 growth/size/body region MP:0005378 10.06 FLVCR1 FXN GJB1 MFN2 MTMR2 NDRG1
4 cellular MP:0005384 10.02 FXN GDAP1 GJB1 LITAF MFN2 MPZ
5 mortality/aging MP:0010768 9.9 FLVCR1 FXN GJB1 MFN2 MPZ MTMR2
6 nervous system MP:0003631 9.53 SPTLC1 FGD4 FXN GDAP1 GJB1 LITAF
7 muscle MP:0005369 9.5 FXN PMP22 SLC12A6 MFN2 NDRG1 NGF

Drugs & Therapeutics for Sensory Peripheral Neuropathy

Drugs for Sensory Peripheral Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Hydroxocobalamin Approved Phase 4,Phase 3,Not Applicable 13422-51-0 11953898 44475014
5
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 68-19-9 44176380
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 59-30-3 6037
7
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 58-05-9 143 6006
8
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 13422-55-4
9
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 66-72-8 1050
10
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4,Not Applicable 54-47-7 1051
11
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 65-23-6 1054
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Anesthetics Phase 4,Phase 3
15 Anesthetics, Local Phase 4
16 Anti-Anxiety Agents Phase 4
17 Anti-Arrhythmia Agents Phase 4,Phase 3
18 Anticonvulsants Phase 4,Phase 3,Phase 2
19 Antimanic Agents Phase 4
20 Antiparkinson Agents Phase 4
21 calcium channel blockers Phase 4,Phase 3
22 Calcium, Dietary Phase 4,Phase 3
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
24 Diuretics, Potassium Sparing Phase 4,Not Applicable
25 Excitatory Amino Acid Antagonists Phase 4,Phase 3
26 Excitatory Amino Acids Phase 4,Phase 3
27 GABA Agents Phase 4
28 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
29 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
30 Sodium Channel Blockers Phase 4,Not Applicable
31 Tranquilizing Agents Phase 4,Phase 3,Phase 2
32 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Vitamin B 12 Phase 4,Phase 3,Not Applicable
35 Vitamin B 6 Phase 4,Phase 3,Not Applicable
36 Vitamin B Complex Phase 4,Phase 3,Not Applicable
37 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38
Cobalamin Nutraceutical Phase 4,Phase 3,Not Applicable 13408-78-1 6438156
39 Folate Nutraceutical Phase 4,Phase 3,Not Applicable
40 Vitamin B12 Nutraceutical Phase 4,Phase 3,Not Applicable
41 Vitamin B9 Nutraceutical Phase 4,Phase 3,Not Applicable
42
Acetylcarnitine Approved, Investigational Phase 3 3040-38-8 1
43
Fluorouracil Approved Phase 3,Not Applicable 51-21-8 3385
44
Oxaliplatin Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
45
Amitriptyline Approved Phase 3,Phase 2 50-48-6 2160
46
Baclofen Approved Phase 3 1134-47-0 2284
47
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
48
Perphenazine Approved Phase 3,Phase 2 58-39-9 4748
49
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
50
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 Anodyne Therapy in Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
2 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
3 Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
4 Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Completed NCT00903851 Phase 4 Lidoderm
5 Clinical Study on Acetyl-L-Carnitine Completed NCT01526564 Phase 3 Acetylcarnitine;Placebo
6 Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer Completed NCT00363129 Phase 3
7 XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy Completed NCT00272051 Phase 3 SR57746A
8 Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. Completed NCT00305188 Phase 3 Xaliproden (SR57746A);Placebo;Oxaliplatin;5-Fluorouracil;Leucovorin
9 Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity Completed NCT01087658 Phase 3 Glutamine;Calcium and Magnesium
10 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
11 Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer Completed NCT02468739 Phase 3 EC-T or TC plus GM1;EC-T or TC plus placebo
12 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed NCT01099449 Phase 3 calcium gluconate;magnesium sulfate;oxaliplatin
13 A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients Completed NCT00659269 Phase 3 Chemotherapy
14 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
15 An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy Completed NCT00791492 Phase 2, Phase 3 Fx-1006A
16 Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer Recruiting NCT02289547 Phase 3 Capecitabine
17 PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA Recruiting NCT03006432 Phase 3 Oxaliplatin;5Fluorouracil bolus;5Fluorouracil continu;Docetaxel;Folinic Acid
18 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
19 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
20 Treatment of Chronic Laryngitis With Amitriptyline Suspended NCT02552225 Phase 2, Phase 3 Amitriptyline
21 Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens Terminated NCT00603577 Phase 3 Placebo;Xaliproden
22 Trial of the Treatment of Chronic Laryngitis With Amitryptiline Terminated NCT02434523 Phase 2, Phase 3 Amitriptyline
23 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
24 Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402) Unknown status NCT02288078 Phase 2 Dexamethasone;Regorafenib;Placebo;Proton pump inhibitor
25 A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy Completed NCT00000842 Phase 2 Nerve Growth Factor, Recombinant Human
26 L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1 Completed NCT01733407 Phase 1, Phase 2 L-serine;placebo
27 Ascorbic Acid Treatment in CMT1A Trial (AATIC) Completed NCT00271635 Phase 2 Placebo;ascorbic acid
28 Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy Completed NCT00952848 Phase 2
29 Effect of C-Peptide on Diabetic Peripheral Neuropathy Completed NCT00278980 Phase 2 C-peptide
30 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors Completed NCT00061893 Phase 2 celecoxib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vinblastine sulfate;vincristine sulfate;MESNA;Filgrastim
31 Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A Completed NCT01401257 Phase 2 PXT3003 Low dose;PXT3003 Intermediate Dose;PXT3003 High Dose
32 Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma Completed NCT00153920 Phase 2 bortezomib
33 Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma Completed NCT00287872 Phase 2 bortezomib;thalidomide
34 Cetuximab and Lenalidomide in Head and Neck Completed NCT01133665 Phase 2 Cetuximab and Lenalidomide
35 Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral Neuropathy Completed NCT01469559 Phase 2 Novolin Toronto insulin;Normal saline
36 Topiramate for Cryptogenic Sensory Peripheral Neuropathy Recruiting NCT02878798 Phase 2 topiramate
37 The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes Recruiting NCT02915263 Phase 2 IGIV-C;0.9% Sodium Chloride
38 Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer Recruiting NCT03502343 Phase 2 Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy
39 IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3 Not yet recruiting NCT03401073 Phase 2 Intravenous immunoglobulin;0.9% Sodium Chloride
40 NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma Not yet recruiting NCT03524898 Phase 1, Phase 2 Nab-Paclitaxel;gemcitabine
41 A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy Terminated NCT00267007 Phase 2 PROCRIT 40,000 IU QW;Placebo
42 NB2013-HR German (GPOH) / Dutch (DCOG) Trial Terminated NCT02641782 Phase 2 antibody ch14.18;GM-CSF;IL-2 i.v.;IL-2 s.c.;Retinoic acid
43 Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient Terminated NCT01955629 Phase 1, Phase 2 Aflibercept AVE0005;Oxaliplatin;Capecitabine
44 Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS) Terminated NCT00231140 Phase 2 Thalidomide (drug)
45 Epoetin Alfa for HIV-Associated Neuropathy Trial Withdrawn NCT00528593 Phase 2 epoetin alfa
46 Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Completed NCT00258245 Phase 1 arsenic trioxide;bortezomib;dexamethasone;thalidomide;Aspirin
47 Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer Completed NCT02174887 Phase 1 Nab-paclitaxel + Gemcitabine
48 Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas Terminated NCT00996346 Phase 1 Irinotecan&Temsirolimus:Arm1, Level 1;Irinotecan&Temsirolimus:Arm 1, Level 2;Irinotecan&Temsirolimus:Arm 2, Level 1
49 L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer Withdrawn NCT02215083 Phase 1
50 Pathology of Skin, Nerve and Vasculature in the Amputated Limb of Diabetes Unknown status NCT00840164

Search NIH Clinical Center for Sensory Peripheral Neuropathy

Cochrane evidence based reviews: hereditary sensory and autonomic neuropathies

Genetic Tests for Sensory Peripheral Neuropathy

Genetic tests related to Sensory Peripheral Neuropathy:

# Genetic test Affiliating Genes
1 Sensory Neuropathy 29

Anatomical Context for Sensory Peripheral Neuropathy

MalaCards organs/tissues related to Sensory Peripheral Neuropathy:

41
Skin, Bone, Liver, Colon, Endothelial, Spinal Cord, Trigeminal Ganglion

Publications for Sensory Peripheral Neuropathy

Articles related to Sensory Peripheral Neuropathy:

(show top 50) (show all 331)
# Title Authors Year
1
Diagnosis of Pure Ulnar Sensory Neuropathy Around the Hypothenar Area Using Orthodromic Inching Sensory Nerve Conduction Study: A Case Report. ( 29961748 )
2018
2
An Isolated Trigeminal Sensory Neuropathy. ( 29977447 )
2018
3
Hereditary sensory neuropathy type 1-associated deoxysphingolipids cause neurotoxicity, acute calcium handling abnormalities and mitochondrial dysfunction in vitro. ( 29778900 )
2018
4
POLG2 deficiency causes adult-onset syndromic sensory neuropathy, ataxia and parkinsonism. ( 28078310 )
2017
5
Cyclic vomiting syndrome after acute autonomic and sensory neuropathy. ( 28244649 )
2017
6
[Clinical and epidemiological characteristics of hereditary motor-sensory neuropathy 1X caused by the mutation c. 259C> G (p. P87A) in the GJB1 gene of patients from the Republic of Bashkortostan]. ( 28399101 )
2017
7
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. ( 28447211 )
2017
8
Structure of the human TRiC/CCT Subunit 5 associated with hereditary sensory neuropathy. ( 28623285 )
2017
9
A novel missense variant (Gln220Arg) of GNB4 encoding guanine nucleotide-binding protein, subunit beta-4 in a Japanese family with autosomal dominant motor and sensory neuropathy. ( 28642160 )
2017
10
FDXR Mutations Cause Sensorial Neuropathies and Expand the Spectrum of Mitochondrial Fe-S-Synthesis Diseases. ( 28965846 )
2017
11
A homozygous FITM2 mutation causes a deafness-dystonia syndrome with motor regression and signs of ichthyosis and sensory neuropathy. ( 28067622 )
2016
12
Prevalence of Sensory Neuropathy in Type 2 Diabetes Mellitus and Its Correlation with Duration of Disease. ( 28166066 )
2016
13
Compound heterozygous intermediate MJD alleles cause cerebellar ataxia with sensory neuropathy. ( 27896316 )
2016
14
TNF Block Gene Variants Associate With Pain Intensity in Black Southern Africans With HIV-associated Sensory Neuropathy. ( 25756557 )
2016
15
Severe sensory neuropathy in patients with adult-onset multiple acyl-CoA dehydrogenase deficiency. ( 26821934 )
2016
16
Painless Ulcers and Fissures of Toes: Hereditary Sensory Neuropathy, Not Leprosy. ( 26955138 )
2016
17
Polymorphisms in CAMKK2 may predict sensory neuropathy in African HIV patients. ( 26785644 )
2016
18
Lidocaine-medicated plaster for treating acute autonomic and sensory neuropathy with erythromelalgia-like presentations. ( 27158041 )
2016
19
Recessive hereditary motor and sensory neuropathy caused by IGHMBP2 gene mutation. ( 26136520 )
2015
20
Anti-Hu antibody-positive paraneoplastic limbic encephalitis with acute motor sensory neuropathy resembling Guillain-BarrAc syndrome: a case study. ( 26511029 )
2015
21
The Variant p.(Arg183Trp) in SPTLC2 Causes Late-Onset Hereditary Sensory Neuropathy. ( 26573920 )
2015
22
X-Linked Hereditary Motor Sensory Neuropathy Type 1 (CMTX1) in a Three-Generation Gelao Chinese Family. ( 26479765 )
2015
23
Re: Scrotal and Perineal Sensory Neuropathy after Urethroplasty for Bulbar Urethral Stricture Disease: An Evaluation of the Incidence, Timing, and Resolution. ( 26088235 )
2015
24
Pathogenic mutations and sequence variants within mitofusin 2 gene in Polish patients with different hereditary motor-sensory neuropathies. ( 26581383 )
2015
25
Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. ( 26015512 )
2015
26
Scrotal and perineal sensory neuropathy after urethroplasty for bulbar urethral stricture disease: an evaluation of the incidence, timing, and resolution. ( 25432846 )
2014
27
A novel missense mutation confirms ATL3 as a gene for hereditary sensory neuropathy type 1. ( 24736309 )
2014
28
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). ( 24513692 )
2014
29
Sensory neuropathy with bone destruction due to a mutation in the membrane-shaping atlastin GTPase 3. ( 24459106 )
2014
30
Biochemical characterization of mutants in chaperonin proteins CCT4 and CCT5 associated with hereditary sensory neuropathy. ( 25124038 )
2014
31
Pain, sleep disturbances, and functional limitations in people living with HIV/AIDS-associated distal sensory peripheral neuropathy. ( 25513029 )
2014
32
Neurofilament light mutation causes hereditary motor and sensory neuropathy with pyramidal signs. ( 25583183 )
2014
33
Tibial sensory neuropathy as a rare complication of percutaneous tibial nerve stimulation. ( 25407114 )
2014
34
Natural History and Biomarkers in Hereditary Sensory Neuropathy Type 1. ( 25042817 )
2014
35
Heat Shock Protein 70 Is Necessary to Improve Mitochondrial Bioenergetics and Reverse Diabetic Sensory Neuropathy following KU-32 Therapy. ( 24263156 )
2014
36
Clinical and neurophysiologic characterization of an European family with hereditary sensory neuropathy, paroxysmal cough and gastroesophageal reflux. ( 24760089 )
2014
37
Pain, Sleep Disturbances, and Functional Limitations in People Living with HIV/AIDS-Associated Distal Sensory Peripheral Neuropathy. ( 23887924 )
2013
38
A polymorphism in IL4 may associate with sensory neuropathy in African HIV patients. ( 23511027 )
2013
39
KCNS1, but not GCH1, is associated with pain intensity in a black southern African population with HIV-associated sensory neuropathy: a genetic association study. ( 23314412 )
2013
40
Acu/Moxa for distal sensory peripheral neuropathy in HIV: a randomized control pilot study. ( 23582399 )
2013
41
A novel familial prion disease causing pan-autonomic-sensory neuropathy and cognitive impairment. ( 23577609 )
2013
42
Spectrum and frequencies of mutations in the MFN2 gene and its phenotypical expression in Czech hereditary motor and sensory neuropathy type II patients. ( 24126688 )
2013
43
Genetics of the Charcot-Marie-Tooth disease in the Spanish Gypsy population: the hereditary motor and sensory neuropathy-Russe in depth. ( 22978647 )
2013
44
Severe sensory neuropathy increases risk of heel pressure ulcer in older adults. ( 24219213 )
2013
45
Mutation in FAM134B causing hereditary sensory neuropathy with spasticity in a Turkish family. ( 24327336 )
2013
46
Polymorphisms in uncoupling protein genes UCP2 and UCP3 are not associated with HIV-associated sensory neuropathy in African individuals. ( 23521650 )
2013
47
Goiter and laryngeal sensory neuropathy. ( 23818901 )
2013
48
Hereditary motor and sensory neuropathy (HMSN) type X1 in an Argentinean family reveals independent GJB1/Cx32 mutations at the identical nucleotide position. ( 23384994 )
2013
49
Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. ( 23776197 )
2013
50
Idiopathic trigeminal sensory neuropathy. A case report. ( 24166572 )
2013

Variations for Sensory Peripheral Neuropathy

ClinVar genetic disease variations for Sensory Peripheral Neuropathy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GDAP1 NM_018972.2(GDAP1): c.715C> T (p.Leu239Phe) single nucleotide variant Pathogenic rs104894080 GRCh37 Chromosome 8, 75276240: 75276240
2 GDAP1 NM_018972.2(GDAP1): c.715C> T (p.Leu239Phe) single nucleotide variant Pathogenic rs104894080 GRCh38 Chromosome 8, 74364005: 74364005
3 MPZ NM_000530.7(MPZ): c.293G> A (p.Arg98His) single nucleotide variant Pathogenic/Likely pathogenic rs121913589 GRCh37 Chromosome 1, 161276653: 161276653
4 MPZ NM_000530.7(MPZ): c.293G> A (p.Arg98His) single nucleotide variant Pathogenic/Likely pathogenic rs121913589 GRCh38 Chromosome 1, 161306863: 161306863
5 SPTLC3 NM_018327.3(SPTLC3): c.448T> C (p.Trp150Arg) single nucleotide variant Likely pathogenic rs755919784 GRCh38 Chromosome 20, 13072400: 13072400
6 SPTLC3 NM_018327.3(SPTLC3): c.448T> C (p.Trp150Arg) single nucleotide variant Likely pathogenic rs755919784 GRCh37 Chromosome 20, 13053048: 13053048
7 POMT1 NM_007171.3(POMT1): c.1859G> A (p.Arg620Gln) single nucleotide variant Uncertain significance rs202140413 GRCh37 Chromosome 9, 134396827: 134396827
8 POMT1 NM_007171.3(POMT1): c.1859G> A (p.Arg620Gln) single nucleotide variant Uncertain significance rs202140413 GRCh38 Chromosome 9, 131521440: 131521440
9 GJB1 NM_001097642.2(GJB1): c.502T> G (p.Cys168Gly) single nucleotide variant Likely pathogenic rs1057518780 GRCh37 Chromosome X, 70444059: 70444059
10 GJB1 NM_001097642.2(GJB1): c.502T> G (p.Cys168Gly) single nucleotide variant Likely pathogenic rs1057518780 GRCh38 Chromosome X, 71224209: 71224209

Expression for Sensory Peripheral Neuropathy

Search GEO for disease gene expression data for Sensory Peripheral Neuropathy.

Pathways for Sensory Peripheral Neuropathy

Pathways related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.4 GDAP1 MAG NGF
2 11.14 GJB1 MPZ PMP22
3
Show member pathways
10.62 MAG NGF NTF3

GO Terms for Sensory Peripheral Neuropathy

Cellular components related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 9.33 MAG MPZ NDRG1
2 synaptic vesicle GO:0008021 9.13 MTMR2 NGF NTF3
3 compact myelin GO:0043218 8.62 MAG PMP22
4 membrane GO:0016020 10.07 FLVCR1 GDAP1 GJB1 LITAF MAG MFN2

Biological processes related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron apoptotic process GO:0043524 9.61 MAG NGF NTF3
2 regulation of neuron differentiation GO:0045664 9.46 NGF NTF3
3 mitochondrial fusion GO:0008053 9.4 GDAP1 MFN2
4 locomotion GO:0040011 9.37 NGF NTF3
5 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.32 MAG MPZ
6 nerve growth factor signaling pathway GO:0038180 9.26 NGF NTF3
7 peripheral nervous system myelin maintenance GO:0032287 9.16 NDRG1 PRX
8 peripheral nervous system development GO:0007422 9.13 NGF NTF3 PMP22
9 nerve development GO:0021675 8.8 NGF NTF3 PRX

Sources for Sensory Peripheral Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....